Sterling’s dedicated bioconjugation facility, located in Deeside, Wales, can handle a variety of batch sizes to support cGMP clinical and preclinical manufacture of antibody drug conjugates (ADCs) and bioconjugates. Through our integrated global network, we are also capable of manufacturing linker payloads at our Wisconsin, US and North Carolina, US facilities.
Our antibody drug conjugation (ADC) manufacturing team possesses experience in GMP production for biotechnology and biologics, supported by experts from across our global contract development and manufacturing organisation.
ADC clinical manufacturing facilities
Our Grade C manufacturing environment is fully flexible and has been designed to accommodate a range of batch sizes, and is equipped with fully customisable and disposable containment.
- Disposable canopy isolator for preparation of linker-payload
- Separate buffer preparation area up to 500L per single buffer
- Option for use of closed-fill manifold systems customisable to fill size and container type
- Conjugation up to 75L reactive volume in glass vessels
- Flexible and adaptable tangential flow filtration (TFF) systems to suit a wide range of input
- AKTA ready chromatography system with gradient up to 500L/h
- Chromatography column up to 20L
We also have a virtual tour around our ADC manufacturing facility
Fast Facts

Capable of manufacturing on gram to kilogram scale

Full-time on site regulatory support and CMC services

Successful MHRA audit and registered with the FDA in 2023
We work closely in partnership with our clients to meet technical requirements and ensure rapid project delivery to support the fast-paced growth within the biologics sector.
Our manufacturing services are also complemented by our expertise in process development and optimisation, as well as analytical method development and characterisation. You can explore more about our antibody drug conjugation services offering here or contact us today.
Deeside, UK
Poster Presentation

